PeptideJournal
Lifestyle17 min read

The Longevity Peptide Protocol: Science of Aging Well

You can't stop aging. But you can change how you age — and a growing body of research suggests peptides may help you do exactly that.

You can't stop aging. But you can change how you age — and a growing body of research suggests peptides may help you do exactly that. From telomere protection to mitochondrial repair, from inflammation control to hormonal optimization, peptides target the biological machinery that drives aging at its roots.

This guide breaks down the science of aging, identifies the peptides with the strongest evidence for each aging pathway, and provides a practical framework for building a longevity-focused protocol.

Table of Contents

Why Aging Happens: The Biology in Plain English

Aging is not a single process. It's a cascade of interconnected breakdowns that accumulate over decades. In 2013, researchers published a landmark paper in Cell identifying nine "hallmarks of aging" — the biological mechanisms that drive age-related decline. That list was updated to twelve hallmarks in 2023.

Here's what actually happens as you age:

Your DNA accumulates damage. Every day, each cell in your body sustains tens of thousands of DNA lesions from normal metabolic activity, UV exposure, and environmental toxins. Young cells repair this damage efficiently. Older cells don't.

Your telomeres shorten. Telomeres are the protective caps on your chromosomes — like the plastic tips on shoelaces. Each time a cell divides, telomeres get a little shorter. When they get too short, the cell stops dividing or dies. Average telomere length decreases by about 24.7 base pairs per year in adults.

Your mitochondria malfunction. Mitochondria produce 90% of your cellular energy. With age, they become less efficient, produce more reactive oxygen species (free radicals), and their own DNA accumulates mutations. By age 70, mitochondrial function can decline by 25-50% compared to age 25.

Chronic inflammation increases. Researchers call it "inflammaging" — a persistent, low-grade inflammatory state that develops with age. Senescent cells (cells that have stopped dividing but refuse to die) pump out inflammatory molecules called the senescence-associated secretory phenotype (SASP). This drives tissue damage throughout the body.

Hormones decline. Growth hormone output drops approximately 14% per decade after age 30. Testosterone, estrogen, DHEA, and melatonin all follow similar trajectories. These hormonal shifts affect muscle mass, bone density, cognitive function, sleep quality, and metabolic health.

Your brain shrinks. Starting around age 35, the brain loses approximately 0.2-0.5% of its volume per year. This accelerates after 60. Neuroinflammation increases, synaptic connections weaken, and neurotransmitter production declines.

The peptides discussed in this guide target multiple hallmarks simultaneously — which is why they've attracted so much attention from longevity researchers.

The Hallmarks of Aging — and the Peptides That Target Them

No single peptide addresses all twelve hallmarks of aging. But several peptides target specific mechanisms with enough preclinical (and in some cases clinical) evidence to warrant serious attention.

Aging HallmarkKey PeptidesEvidence Level
Telomere attritionEpitalonPreclinical + limited human
Mitochondrial dysfunctionMOTS-c, Humanin, SS-31Preclinical to Phase 2 clinical
Chronic inflammationBPC-157, KPV, Thymosin Alpha-1Preclinical to Phase 3 clinical
Hormonal declineCJC-1295, Ipamorelin, SermorelinModerate clinical
NeurodegenerationSemax, Selank, DihexaPreclinical + limited human
Cellular senescenceFOXO4-DRI (experimental)Early preclinical
Skin/connective tissue agingGHK-CuModerate clinical

Let's examine each category in depth.

Telomere Protection: Epitalon and the Telomerase Connection

Telomere shortening is one of the most measurable aspects of biological aging. When telomeres reach a critical length, cells enter senescence or apoptosis. The enzyme telomerase can rebuild telomere length — but most adult cells produce very little of it.

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on a natural peptide called epithalamin, produced by the pineal gland. It was developed by Russian gerontologist Vladimir Khavinson, who spent over 30 years researching it.

What the research shows:

  • In human cell cultures, epitalon activated telomerase and extended telomere length in somatic cells, enabling them to divide beyond the normal Hayflick limit (the maximum number of times a cell can divide).
  • A study on elderly patients showed that epithalamin treatment was associated with a 28% reduction in mortality over a 6-year follow-up period compared to controls.
  • In pinealectomized rats, epitalon restored melatonin production — relevant because melatonin itself has anti-aging properties.
  • Khavinson's research group reported that epitalon treatment in rats increased their maximum lifespan by approximately 13.3%.

Evidence quality reality check: Most of the human data comes from Russian studies published in journals with limited international peer review. The telomerase activation data from cell cultures is more robust. No large-scale, double-blind, placebo-controlled trial has been conducted in Western research institutions.

Typical research protocols: 5-10 mg daily via subcutaneous injection for 10-20 day cycles, repeated 2-3 times per year. Some practitioners use longer cycles with lower doses.

Mitochondrial Rescue: MOTS-c, Humanin, and SS-31

Mitochondrial dysfunction sits at the heart of aging. When your cellular power plants fail, everything downstream suffers — energy production, cellular repair, inflammation control, and metabolic regulation.

Three peptides stand out in mitochondrial longevity research.

MOTS-c: The Exercise Mimetic

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded by mitochondrial DNA. It's one of a small group of "mitochondrial-derived peptides" (MDPs) — signaling molecules produced by your own mitochondria.

MOTS-c levels decline with age. In skeletal muscle, circulating MOTS-c concentrations drop significantly in older adults compared to younger individuals. This decline correlates with reduced metabolic function.

What makes MOTS-c remarkable is its role as an exercise mimetic. It activates AMPK (the same metabolic sensor activated by exercise and fasting), improves insulin sensitivity, and promotes fatty acid oxidation. In mice, MOTS-c treatment improved physical performance in aged animals, reversed age-dependent insulin resistance, and protected against diet-induced obesity.

A 2023 study showed that MOTS-c levels in centenarians were significantly higher than in age-matched controls — suggesting a correlation between MOTS-c levels and exceptional longevity.

Humanin: The Cell Protector

Humanin was the first mitochondrial-derived peptide discovered, identified in 2001 during Alzheimer's disease research. It's a 24-amino acid peptide with broad cytoprotective effects.

Humanin protects cells from apoptosis (programmed cell death), reduces oxidative stress, and improves mitochondrial function. Like MOTS-c, humanin levels decline with age and are higher in long-lived individuals. Studies have found that humanin levels are inversely correlated with IGF-1 levels — mirroring the pattern seen in long-lived animal species and centenarians.

The research is largely preclinical, but humanin analogs (particularly HNG, a potent synthetic version) have shown promise in animal models of Alzheimer's disease, cardiovascular disease, and diabetes.

SS-31 (Elamipretide): The Closest to the Clinic

SS-31, now called elamipretide, is a synthetic tetrapeptide that targets the inner mitochondrial membrane. Unlike most antioxidants that work broadly throughout the cell, SS-31 concentrates specifically in mitochondria — where oxidative damage does the most harm.

SS-31 has the strongest clinical evidence of any mitochondrial peptide. It reached Phase 2 and Phase 3 clinical trials for Barth syndrome (a mitochondrial disease), primary mitochondrial myopathy, and heart failure. Trial results have been mixed — the Barth syndrome trial showed functional improvements, while the heart failure trial did not meet its primary endpoint.

For longevity purposes, the preclinical data is compelling. In aged mice, SS-31 treatment reversed age-related mitochondrial dysfunction in skeletal muscle, improved exercise tolerance, and reduced oxidative damage. It essentially made old mitochondria perform more like young ones.

Taming Chronic Inflammation: BPC-157, KPV, and Thymosin Alpha-1

Chronic, low-grade inflammation is the common thread connecting virtually every age-related disease — heart disease, cancer, diabetes, Alzheimer's, arthritis. Controlling inflammaging is arguably the highest-leverage intervention for longevity.

BPC-157: The Multi-System Healer

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protective protein found in human gastric juice. Its anti-inflammatory effects are well-documented across hundreds of animal studies.

BPC-157 works through multiple mechanisms relevant to aging: it modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), protects the endothelium (blood vessel lining), and reduces inflammatory cytokines. It has shown tissue-protective effects in the gut, brain, liver, muscle, tendon, and bone.

For longevity, BPC-157's most relevant property may be its systemic anti-inflammatory action. In animal models, it reduces markers of oxidative stress and inflammation across multiple organ systems simultaneously.

Evidence quality: Extensive preclinical data (hundreds of studies), but no completed human clinical trials as of early 2026. A Phase 2 trial for ulcerative colitis has been initiated.

KPV: The Targeted Anti-Inflammatory

KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It has potent anti-inflammatory properties that work primarily through inhibiting NF-kB — the master inflammatory signaling pathway.

Research shows KPV reduces intestinal inflammation in colitis models, protects against skin inflammation, and modulates immune responses without the immune suppression seen with steroids. For longevity, its targeted action on NF-kB makes it relevant because NF-kB activity increases with age and drives many inflammaging processes.

Thymosin Alpha-1: The Immune Optimizer

Thymosin Alpha-1 is an FDA-approved peptide (in several countries outside the US) that modulates immune function. It doesn't suppress the immune system — it optimizes it, boosting underperforming immune responses while calming overactive ones.

With age, the thymus gland shrinks (thymic involution), and immune function declines — a process called immunosenescence. Thymosin Alpha-1 partially compensates for this by promoting T-cell maturation and improving the balance between Th1 and Th2 immune responses.

It has the strongest clinical evidence in the inflammation category, with studies in hepatitis B, hepatitis C, cancer (as an adjunct to chemotherapy), and vaccine response in elderly patients.

Hormonal Optimization: Growth Hormone Peptides and Beyond

Growth hormone (GH) output declines approximately 14% per decade after 30. By age 60, many people produce less than half the GH they did at 25. This "somatopause" contributes to muscle loss, increased body fat, reduced bone density, thinner skin, and impaired recovery.

Direct GH replacement (injecting synthetic human growth hormone) carries significant risks: insulin resistance, joint pain, fluid retention, and potentially increased cancer risk. Growth hormone-releasing peptides offer a more physiological approach by stimulating your own GH production.

CJC-1295 and Ipamorelin: The Standard Combination

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce GH. Ipamorelin is a growth hormone-releasing peptide (GHRP) that works through a different receptor — the ghrelin receptor.

Used together, they produce a synergistic GH release that mimics the body's natural pulsatile pattern more closely than direct GH injection. The GH elevation is significant but bounded — your pituitary can only produce so much, which provides a natural safety ceiling.

For longevity purposes, the CJC-1295/Ipamorelin combination targets multiple age-related changes: improved body composition (more muscle, less fat), better sleep quality, faster recovery from exercise, and improved skin thickness and elasticity.

Evidence quality: Moderate. CJC-1295 has Phase 2 clinical trial data showing significant GH and IGF-1 elevation. Ipamorelin has clinical data confirming selective GH release with minimal cortisol or prolactin elevation. The combination has not been studied in large clinical trials for longevity specifically. See our peptide stacking guide for more on this combination.

Tesamorelin: The FDA-Approved Option

Tesamorelin is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy. It reduces visceral adipose tissue and has shown positive effects on liver fat, cognitive function, and cardiovascular risk markers. For longevity-minded practitioners, tesamorelin represents the most "legitimate" GH peptide option — it has FDA approval, a strong safety profile, and robust clinical data.

Cognitive Longevity: Protecting the Aging Brain

Brain aging drives some of the most feared aspects of getting older. Cognitive decline, memory loss, and neurodegenerative disease affect quality of life more than almost any other aging process. Several peptides show neuroprotective and cognitive-enhancing properties.

Semax and Selank: Neuroprotection From Russian Research

Semax is a synthetic analog of ACTH (4-10) that has been approved in Russia since 1996 for cognitive disorders and stroke recovery. It increases brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival, growth, and synaptic plasticity. BDNF levels decline with age and are reduced in Alzheimer's disease.

Selank is a synthetic analog of the immune peptide tuftsin, also approved in Russia. It has anxiolytic (anti-anxiety) effects comparable to benzodiazepines but without sedation or dependency. Selank also modulates serotonin, dopamine, and norepinephrine systems and has shown neuroprotective properties in preclinical models.

For longevity, the combination targets two aspects of brain aging: cognitive performance (Semax) and stress/anxiety regulation (Selank). Chronic stress accelerates brain aging through cortisol-mediated hippocampal damage — making anxiety management a legitimate longevity strategy. See the best peptides for cognitive enhancement for a deeper comparison.

Dihexa: High Potency, High Uncertainty

Dihexa is an angiotensin IV analog that has shown potency seven orders of magnitude greater than BDNF at promoting synaptic connections in preclinical studies. It crosses the blood-brain barrier, which is unusual for peptides. However, dihexa remains entirely in the preclinical stage, with no human studies completed. Its extreme potency cuts both ways — the same powerful neuroplasticity that could help could also carry unknown risks.

Skin and Connective Tissue: Aging You Can See

Skin aging is the most visible marker of biological aging. Collagen production drops approximately 1-1.5% per year starting in the mid-20s. Elastin fibers degrade. Wound healing slows. The dermal layer thins.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is the standout peptide for skin and connective tissue longevity. Discovered over 50 years ago, GHK-Cu has been shown to:

  • Stimulate collagen synthesis (types I and III)
  • Promote elastin production
  • Recruit immune cells to wound sites
  • Reduce inflammation and oxidative damage
  • Activate over 4,000 genes, with a pattern that shifts gene expression toward a younger profile

GHK-Cu has both topical and injectable applications. Topical GHK-Cu is available in numerous skincare products and has clinical evidence supporting wrinkle reduction, skin firmness improvement, and photoaging reversal. Injectable GHK-Cu is used by some practitioners for systemic anti-aging effects, though clinical data for injectable use is limited. For a broader look at peptide skincare, see our guide to best peptides for anti-aging.

Building a Longevity Peptide Protocol

A well-designed longevity protocol doesn't throw every peptide at the wall. It targets your specific aging vulnerabilities, starts conservatively, and builds systematically.

Step 1: Assess Your Baseline

Before starting any peptide protocol, establish baseline measurements:

  • Blood work: Complete metabolic panel, IGF-1, inflammatory markers (hs-CRP, IL-6, TNF-alpha), hormonal panel (GH, testosterone/estrogen, DHEA-S, thyroid), fasting insulin, HbA1c
  • Body composition: DEXA scan for precise muscle mass, fat mass, and bone density
  • Cognitive baseline: Validated assessments (MoCA, or digital cognitive testing platforms)
  • Biological age testing: Epigenetic clocks (GrimAge, PhenoAge) offer the most scientifically validated measure of biological vs. chronological age
  • Telomere length: Available through specialized testing (though interpretation remains debated)

Step 2: Prioritize Your Targets

Based on your assessment, identify which aging pathways need the most attention:

If You See...Priority TargetKey Peptides
High hs-CRP, elevated IL-6InflammationBPC-157, KPV, Thymosin Alpha-1
Low IGF-1, poor body compositionHormonal optimizationCJC-1295/Ipamorelin, Tesamorelin
Short telomeres, accelerated epigenetic ageCellular agingEpitalon, GHK-Cu
Declining cognitive scores, family history of neurodegenerationBrain protectionSemax, Selank
Poor mitochondrial function, exercise intoleranceMitochondrial healthMOTS-c (research stage)

Step 3: Start With One Peptide

The beginner's guide to peptide therapy applies here — resist the urge to start five peptides simultaneously. You won't know what's working, what's causing side effects, or what to adjust.

For most people, a reasonable starting point is:

  • If inflammation is your primary concern: BPC-157 (the broadest evidence base for tissue protection)
  • If hormonal decline is the priority: CJC-1295/Ipamorelin (well-characterized, predictable response)
  • If cognitive protection is the goal: Semax (most clinical evidence among nootropic peptides)
  • If visible aging concerns you most: GHK-Cu topical (low risk, demonstrated efficacy)

Run your first peptide for 8-12 weeks. Monitor subjective effects (energy, sleep, recovery, mood) and get follow-up bloodwork at the 8-week mark.

Step 4: Add Compounds Strategically

After establishing a baseline response with your first peptide, consider adding one peptide targeting a different pathway. The peptide cycling guide outlines how to structure on/off periods.

Example longevity protocol build (over 6-12 months):

  • Month 1-3: CJC-1295/Ipamorelin (hormonal optimization)
  • Month 2-4: Add BPC-157 cycle (anti-inflammatory, tissue protection)
  • Month 4-6: Add Semax (neuroprotection, BDNF upregulation)
  • Twice yearly: Epitalon 20-day cycle (telomere maintenance)
  • Ongoing: GHK-Cu topical daily (skin, connective tissue)

Step 5: Monitor and Adjust

Repeat comprehensive blood work every 3-6 months. Track IGF-1 (should increase with GH peptides but not exceed upper normal range), inflammatory markers (should decrease), and metabolic markers. Adjust doses, cycling schedules, and peptide selection based on objective data.

Work with a practitioner experienced in peptide therapy. Our guide on choosing a peptide therapy clinic can help you find one.

Evidence Quality: What We Know vs. What We Hope

Honesty about evidence quality is what separates education from marketing. Here's where each longevity peptide actually stands:

Strong clinical evidence (Phase 2-3 trials, FDA-approved uses):

  • Tesamorelin (FDA-approved, robust trial data)
  • Thymosin Alpha-1 (approved in multiple countries, extensive clinical data)
  • SS-31/Elamipretide (Phase 2-3 trials, mixed results)

Moderate clinical evidence (smaller human studies, Phase 1-2 data):

  • CJC-1295 (Phase 2 data for GH release)
  • Ipamorelin (clinical data for GH selectivity)
  • Semax (approved in Russia, clinical data from Russian studies)
  • GHK-Cu topical (clinical studies for skin aging)

Primarily preclinical evidence (animal studies, in vitro data):

  • BPC-157 (hundreds of animal studies, no completed human trials)
  • MOTS-c (compelling preclinical data, human correlational studies)
  • Humanin (preclinical studies and observational human data)
  • Epitalon (limited human studies, primarily Russian research)
  • KPV (preclinical models)
  • Selank (Russian clinical data, limited Western research)

Early research (limited preclinical data):

  • Dihexa (preclinical only)
  • FOXO4-DRI (early preclinical)

This does not mean preclinical peptides don't work. It means we don't have the same confidence in their safety and efficacy as we do for clinically tested compounds.

Realistic Expectations for Peptide-Based Longevity

Peptides are not a longevity shortcut. They're tools — potentially powerful ones — that work best as part of a comprehensive approach. Here's what you can realistically expect:

What peptides can do:

  • Optimize hormone levels that decline with age
  • Reduce chronic inflammation
  • Support tissue repair and recovery
  • Potentially improve mitochondrial function
  • Protect and improve skin quality
  • Support cognitive function

What peptides can't do:

  • Reverse decades of aging
  • Replace exercise, nutrition, and sleep
  • Cure neurodegenerative diseases
  • Guarantee extended lifespan
  • Work in isolation from overall health practices

Realistic timeline: Most people report noticeable improvements in sleep quality, recovery, energy, and body composition within 4-12 weeks of starting GH peptides. Anti-inflammatory effects may be noticed within 2-4 weeks. Skin improvements from GHK-Cu typically appear after 8-12 weeks of consistent use. Cognitive effects from nootropic peptides are often subtle and develop over weeks to months. See the peptide therapy timeline for more details.

The most evidence-supported longevity interventions remain caloric restriction (or time-restricted eating), regular exercise (both aerobic and resistance training), quality sleep, stress management, and social connection. Peptides should complement these foundations, not replace them.

Frequently Asked Questions

What is the best single peptide for longevity? There is no single best peptide because aging involves multiple pathways. If forced to choose one, CJC-1295/Ipamorelin addresses the hormonal decline that affects the most systems — body composition, sleep, recovery, skin quality, and metabolic health. But the "best" choice depends on your individual health status and goals.

How long do you need to take longevity peptides? Most longevity protocols are ongoing, with cycling periods. GH peptides are typically used in cycles of 3-6 months on, 1-2 months off. Epitalon is used in shorter cycles (10-20 days) 2-3 times per year. Topical GHK-Cu can be used daily long-term. Your peptide cycling protocol should be designed with a practitioner.

Are longevity peptides safe long-term? Long-term safety data is limited for most peptides used for longevity. Tesamorelin and Thymosin Alpha-1 have the most safety data (years of clinical use). GH peptides carry theoretical concerns about chronically elevated IGF-1 and cancer risk, which is why cycling and monitoring are important. Work with a doctor who can track relevant biomarkers.

Can you combine longevity peptides with rapamycin or metformin? Many longevity-focused practitioners do combine peptides with pharmaceutical interventions like low-dose rapamycin (an mTOR inhibitor) or metformin (an AMPK activator). However, interactions are poorly studied. GH peptides increase IGF-1, while rapamycin inhibits mTOR (which is downstream of IGF-1 signaling) — these work in opposite directions, which raises questions about combined use. Discuss any combinations with your healthcare provider.

How much does a longevity peptide protocol cost? Costs vary widely. A basic CJC-1295/Ipamorelin protocol from a compounding pharmacy runs approximately $150-350/month. Adding additional peptides increases costs proportionally. Blood work monitoring adds $200-500 per panel. Epigenetic age testing costs $200-400 per test. A comprehensive protocol with monitoring can run $500-1,500/month.

At what age should you start thinking about longevity peptides? Most practitioners recommend starting GH peptides and anti-inflammatory protocols in your late 30s to mid-40s, when age-related hormonal and inflammatory changes become measurable. Starting earlier (late 20s-early 30s) is not harmful for most peptides but may not be necessary. Starting later (50s-60s) can still produce meaningful results. Baseline testing at any age helps identify which interventions make sense for you.

The Bottom Line

A longevity peptide protocol is not a magic bullet. It's a targeted, evidence-informed approach to addressing the specific biological mechanisms that drive aging. The strongest evidence supports peptides that optimize hormonal function, reduce chronic inflammation, protect mitochondrial health, and maintain connective tissue.

Build your protocol around objective data — baseline blood work, biological age testing, and regular monitoring. Start with one peptide, establish its effects, then add strategically. Work with a knowledgeable practitioner. Maintain the lifestyle foundations that no peptide can replace.

The science of peptide-based longevity is still young. Much of the evidence is preclinical. But for those willing to be informed early adopters, peptides offer tools to target aging at its biological roots — not just its symptoms.

References

  1. Lopez-Otin, C., et al. "The Hallmarks of Aging." Cell, vol. 153, no. 6, 2013, pp. 1194-1217.
  2. Lopez-Otin, C., et al. "Hallmarks of aging: An expanding universe." Cell, vol. 186, no. 2, 2023, pp. 243-278.
  3. Khavinson, V., et al. "Peptide epitalon activates chromatin at the old age." Neuroendocrinology Letters, vol. 24, no. 5-6, 2003, pp. 329-333.
  4. Lee, C., et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, vol. 21, no. 3, 2015, pp. 443-454.
  5. Hashimoto, Y., et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proceedings of the National Academy of Sciences, vol. 98, no. 11, 2001, pp. 6336-6341.
  6. Szeto, H.H. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology, vol. 171, no. 8, 2014, pp. 2029-2050.
  7. Sikiric, P., et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, vol. 17, no. 16, 2011, pp. 1612-1632.
  8. Pickart, L., et al. "GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes." Cosmetics, vol. 2, no. 3, 2015, pp. 236-247.
  9. Teichman, S.L., et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, 2006, pp. 799-805.
  10. Ashmarin, I.P., et al. "Semax, an ACTH (4-10) analogue with nootropic properties." CNS Drug Reviews, vol. 11, no. 1, 2005, pp. 17-26.
  11. Zatolokin, P.A., et al. "Effects of Thymosin Alpha-1 on immune function in elderly patients." Immunology Letters, vol. 178, 2016, pp. 44-48.
  12. Reynolds, J.M., et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, vol. 12, 2021, 470.